The duodenal-jejunal bypass liner (EndoBarrier®) for the treatment of type 2 diabetes mellitus in obese patients – efficacy and factors predicting optimal effects
Marek Beneš Orcid.org 1, Tomáš Hucl Orcid.org 1, Pavel Drastich Orcid.org 1, Radan Keil Orcid.org 2, Zuzana Vlasáková Orcid.org 3, Tereza Pelikánová Orcid.org 3, Petra Kaválková4, Miloš Mráz5, Zdeňka Lacinová5,6, Martin Haluzík Orcid.org 4,6, Julius Špičák Orcid.org 1
+ Affiliation
Summary
Summary: Background: The global increase in the incidence of obesity results in an increase in the incidence of type 2 diabetes mellitus (T2DM). Surgical treatment has proven to be effective; however, it carries a high risk of complications. The duodenal-jejunal bypass liner (DJBL) EndoBarrier® (GI Dynamics). is an endoscopic implant that mimics the intestinal bypass portion of the
Roux-en-Y gastric bypass. Material and Methods: Twenty patients were included in the study. They had a mean body mass index (BMI) of 41.9 ± 1.0 kg/sqmand a mean HbA1c concentration of 73.5 ± 4.46 mmol/mol and were receiving T2DM treatment. All patients received complete bariatric support care from a professional team. The aim of this prospective multi-center study was to determine the effectiveness of the DJBL and to identify clinical factors associated with a better outcome of the DJBL. Results: At 10 months, there was significantly greater weight loss (119.56 ± 3.65 vs. 130.3 ± 3.6 kg; p < 0.05), BMI improvement (38.3 ± 1.01 vs. 41.9 ± 1.0 kg/sqm;p < 0.05), excess weight loss of 23%, and improvement of blood glucose levels (8.5 ± 0.5 vs. 11.9 ± 0.83 mmol; p < 0.05) and long--term diabetes compensation (HbA1c, 56.5 ± 3.28 vs. 73.35 ± 4.46 mmol/mol; p < 0.05). Mild abdominal pain and nausea were experienced by 72% of patients during the first 14 days after implantation, 33% of patients during the first month, and 10% of patients after one month. Lower initial BMI, distal position of the anchor, and lower body height were identified as prognostic factors for pain. Conclusion: The DJBL is a safe and effective alternative to surgical bariatric procedures. Lower initial BMI and lower body height could be positive prognostic factors for the superior effect of DJBL treatment.
Keywords
EndoBarrier, bariatric endoscopy, metabolic syndromeTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Centers for Disease Control and Prevention. Obesity and overweight. [online]. Available from: http:/ / www.cdc.gov/ nchs/ fastats/ obesity-overweight.htm.
2. Johnson DA. Preface. Gastroenterologic issues in the obese patient. Gastroenterol Clin North Am 2010; 39(1): xi– xiii. doi:10.1016/ j.gtc.2009.12.013.
3. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39(1): 1– 7. doi: 10.1016/ j.gtc.2009.12.014.
4. Sjöström L, Narbro K, Sjöström CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357(8): 741– 752.
5. Morino M, Toppino M, Forestieri P et al. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 2007; 246(6):1002– 1007.
6. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 2004; 199(4): 543– 551.
7. Coté GA, Edmundowicz SA. Emerging technology: endoluminal treatment of obesity. Gastrointest Endosc 2009; 70(5):991– 999. doi: 10.1016/ j.gie.2009.09.016.
8. Ellsmere JC, Thompson CC, Brugge WR et al. Endoscopic interventions for weight loss surgery. Obesity (Silver Spring) 2009;17(5): 929– 933.
9. Schouten R, Rijs CS, Bouvy ND et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251(2): 236– 243.doi: 10.1097/ SLA.0b013e3181bdfbff.
10. Kumar N. Endoscopic therapy for weight loss: gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastrointest Endosc 2015; 7(9): 847– 859.doi: 10.4253/ wjge.v7.i9.847.
11. Rodriguez-Grunert L, Galvao Neto MP, Alamo M et al. First human experience with endoscopically delivered and retrieved duodenal– jejunal bypass sleeve. Surg ObesRelat Dis 2008; 4(1): 55– 59. doi: 10.1016/ j.soard.2007.07.012.
12. Tarnoff M, Rodriguez L, Escalona A et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for preoperative weight loss in bariatric surgery. Surg Endosc 2009; 23(3): 650– 656. doi: 10.1007/ s00464-008-0125-4.
13. Gersin KS, Rothstein RI, Rosenthal RJ et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 2010; 71(6): 976– 982. doi: 10.1016/ j.gie.2009.11.051.
14. Sandler BJ, Rumbaut R, Swain CP et al.Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve.Surg Endosc 2011; 25(9): 3028– 3033. doi:10.1007/ s00464-011-1665-6. 15. Rubino F, Schauer PR, Kaplan LM et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393– 411. doi: 10.1146/ annurev.med.051308.105148.
16. Cohen R, le Roux CW, Papamargaritis D et al. Role of proximal gut exclusion from food on glucose homeostasis in patients with type 2 diabetes. Diabet Med 2013; 30(12): 1482– 1486. doi: 10.1111/ dme.12268.
17. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond)2009; 33 (Suppl 1): S33– S40. doi: 10.1038/ijo.2009.15.
18. Sjöström L, Lindroos AK, Peltonen M at al. Lifestyle, diabetes and cardiovascular risc factors 10 years after bariatric surgery. N Engl J Med 2004, 351(26): 2683– 2693.